1. In an unselected adult renal transplant population, FK506 as the primary immunosuppressive agent yielded one- and 2-year actuarial patient survival rates of 95% and 93% and one- and 2-year actuarial graft survival rates of 89% and 83%, respectively. Forty-nine percent of successfully transplanted patients were weaned off steroids. 2. In pediatric renal transplant patients, FK506 has been associated with 100% one- and 3-year actuarial patient survival rates and 98% and 85% one- and 3-year actuarial graft survival rates, respectively. Sixty-two percent of successfully transplanted patients were taken off prednisone, with dramatic improvements in height. 3. FK506 has been used successfully in rescuing 70-74% of adult or pediatric renal tran...
An account is given of the 6- to 12-month survival, and causes of failure in 110 consecutive patient...
1. The introduction of combined CsA and steroid treatment as the baseline immunosuppressive medicati...
FK 506 was given for immunosuppression in 14 liver recipients. The drug was used in the first 10 cas...
The experimental immunosuppressive drug FK 506 was given to 36 renal transplant recipients, many of ...
FK 506 was used as a primary immunosuppressive agent in 125 cases of renal transplantation in a rand...
FK506 is a potent immunosuppressive agent which is undergoing clinical testing in liver, kidney, hea...
Previous clinical evaluation of FK506 in renal transplantation has demonstrated equivalent patient a...
A group of 204 adult patients was entered into a prospective, randomized trial comparing FK506/pred-...
The new immunosuppressive drug FK 506 was used from the outset with low doses of prednisone to treat...
FK 506 is a superior immunosuppressive agent that should improve the grafting of organs that already...
FK506 (Prograf) is a new immunosuppressive agent, recently approved for use in solid organ transplan...
The new immunosuppressive agent FK 506 was used as primary immunotherapy in conjunction with low-dos...
Objective: The efficacy for primary orthotopic liver transplantation of a new immunosuppressive agen...
Seventy-seven patients with ongoing acute rejection on initial CsA therapy were converted to FK506 t...
BACKGROUND: Outcome after renal transplantation in children has been variable. We undertook a retros...
An account is given of the 6- to 12-month survival, and causes of failure in 110 consecutive patient...
1. The introduction of combined CsA and steroid treatment as the baseline immunosuppressive medicati...
FK 506 was given for immunosuppression in 14 liver recipients. The drug was used in the first 10 cas...
The experimental immunosuppressive drug FK 506 was given to 36 renal transplant recipients, many of ...
FK 506 was used as a primary immunosuppressive agent in 125 cases of renal transplantation in a rand...
FK506 is a potent immunosuppressive agent which is undergoing clinical testing in liver, kidney, hea...
Previous clinical evaluation of FK506 in renal transplantation has demonstrated equivalent patient a...
A group of 204 adult patients was entered into a prospective, randomized trial comparing FK506/pred-...
The new immunosuppressive drug FK 506 was used from the outset with low doses of prednisone to treat...
FK 506 is a superior immunosuppressive agent that should improve the grafting of organs that already...
FK506 (Prograf) is a new immunosuppressive agent, recently approved for use in solid organ transplan...
The new immunosuppressive agent FK 506 was used as primary immunotherapy in conjunction with low-dos...
Objective: The efficacy for primary orthotopic liver transplantation of a new immunosuppressive agen...
Seventy-seven patients with ongoing acute rejection on initial CsA therapy were converted to FK506 t...
BACKGROUND: Outcome after renal transplantation in children has been variable. We undertook a retros...
An account is given of the 6- to 12-month survival, and causes of failure in 110 consecutive patient...
1. The introduction of combined CsA and steroid treatment as the baseline immunosuppressive medicati...
FK 506 was given for immunosuppression in 14 liver recipients. The drug was used in the first 10 cas...